GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Policy Acquisition Expense

Mesoblast (Mesoblast) Policy Acquisition Expense


View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Mesoblast (Mesoblast) Business Description

Industry
Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.